^
Association details:
Biomarker:LDHA elevation
Cancer:Acute Myelogenous Leukemia
Drug:azacitidine (DNMT inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Upregulated Hif-1a signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine - Data from the Hellenic MDS study group

Published date:
12/17/2020
Excerpt:
We herein investigated the possible association of the Hif-1α signaling pathway with response to 5-AZA therapy in MDS/AML patients. Our data demonstrated that 5- AZA-responders present with higher Hif-1α mRNA and protein expression compared to 5-AZA-non-responders/stable disease patients, before the initiation of therapy...Kaplan-Meier survival analysis revealed a significant correlation between high Hif-1α mRNA expression and better survival rates, while logistic regression analysis showed that Hif-1α mRNA expression is an independent predictor of response to 5-AZA therapy. Moreover, we found that 5-AZA-responders exhibited elevated mRNA levels of the Hif-1α downstream targets LDHa and BNIP3L, a further indication of an overactivated Hif-1a signaling pathway in these patients.
DOI:
10.1002/hon.2834